The topic is short and compact
The twelve-week stability test is the critical path and cannot be shortened, only started earlier.
Packaging decisions are the most common reason for delay, because all tests must be carried out on the final packaging.
A realistic timeframe is six to nine months from the briefing to delivery, provided work is done in parallel rather than sequentially.
When a cosmetic launch fails, production is usually blamed. In practice, production is rarely the problem. A released, tested formulation can be manufactured in four to eight weeks. The weeks prior are lost: in briefings that are too vague, in packaging decisions that remain open, and in testing that starts too late.
The crucial point is that several of these steps depend on one another. Stability testing cannot begin until the formulation and packaging are finalized. The safety assessment cannot be completed until the test results are available. Each week of indecision at the beginning therefore postpones the end by exactly that week, regardless of how quickly work is carried out later.
Vague briefing: Without a defined target group, price point, and efficacy claim, sample loops are created that are purely for clarification purposes.
Open packaging decision: Blocks the start of all packaging-related tests.
Late determination of advertising claims: Determines the scope of testing and thus the duration.
Those who want to shorten the time-to-market do not therefore need to produce faster, but must make decisions earlier. A realistic look at the development duration makes visible which steps can actually be accelerated.
Why launches get delayed and what is not to blame
When a cosmetic launch fails, production is usually blamed. In practice, production is rarely the problem. A released, tested formulation can be manufactured in four to eight weeks. The weeks prior are lost: in briefings that are too vague, in packaging decisions that remain open, and in testing that starts too late.
The crucial point is that several of these steps depend on one another. Stability testing cannot begin until the formulation and packaging are finalized. The safety assessment cannot be completed until the test results are available. Each week of indecision at the beginning therefore postpones the end by exactly that week, regardless of how quickly work is carried out later.
Vague briefing: Without a defined target group, price point, and efficacy claim, sample loops are created that are purely for clarification purposes.
Open packaging decision: Blocks the start of all packaging-related tests.
Late determination of advertising claims: Determines the scope of testing and thus the duration.
Those who want to shorten the time-to-market do not therefore need to produce faster, but must make decisions earlier. A realistic look at the development duration makes visible which steps can actually be accelerated.
The critical path: What cannot be shortened
Some steps are physically or regulatorily fixed. The accelerated stability test over twelve weeks at elevated temperature is the most important of these. It simulates the aging of the product and is the basis for the shelf life specification. These twelve weeks cannot be compressed, otherwise the result will not bear any reliable statement about shelf life.
The preservation challenge test, which can run in parallel but has its own runtime, is also fixed, as is the subsequent safety assessment by a qualified person. The procurement of primary packaging requiring tooling also has lead times that exist independently of development progress.
Stability testing: twelve weeks, cannot be shortened, can only be started earlier.
Preservation challenge test: own runtime, can be parallelized.
Safety assessment and notification: only after all test results are available.
Packaging procurement: lead time independent of formulation progress.
The only effective lever on these steps is the start time. Anyone who starts the stability test four weeks earlier will launch four weeks earlier. This requires that the formulation and packaging are finalized four weeks earlier.
The biggest time-waster: the pending packaging decision
In most delayed projects, the delay can be traced back to a single point: the packaging was determined too late. This has significant consequences because the formulation and packaging must be tested as a system. Components of the packaging can migrate into the formulation, and the packaging can bind preservatives, causing the effective concentration to fall below the validated threshold.
If the packaging is changed after the tests have been completed, the results become invalid. The twelve weeks start all over again. A packaging change in week ten therefore does not cost two weeks, but twelve. This asymmetry is regularly underestimated in planning.
Define the packaging bindingly before the start of the testing phase, do not keep it open in parallel.
Use sample packaging from series production, not from prototype construction.
If there are multiple candidates, it is better to test two variants in parallel than to switch later.
The last point is the most effective compromise: Two packaging variants tested in parallel cost slightly more testing effort, but not twelve weeks. If you want to keep dates predictable, you can find further approaches under planbare Launch-Termine.
Define advertising claims early because they determine the scope of testing
Advertising claims are often treated as a marketing topic and formulated late. Technically, they are a scheduling matter. Every efficacy claim must be proven in accordance with Regulation (EU) No. 655/2013, and the required proof determines which studies are necessary and how long they will take.
A claim of moisturizing effects over 24 hours requires an instrumental application study with its own time requirements. A claim regarding skin compatibility on sensitive skin requires a dermatological test. If these claims are only defined when the packaging has already been designed, the proof is missing, and either the launch is postponed or the claim must be deleted and the packaging reprinted.
Define efficacy claims before starting test planning, not after packaging design.
Identify the required proof and its duration for each claim.
Discard claims without reliable proof early instead of deleting them late.
This discipline takes a few days in the concept phase and regularly prevents delays of several weeks shortly before launch.
Work in parallel instead of sequentially
The second major lever is the process logic. Many projects run sequentially: first formulation, then packaging, then testing, then regulatory affairs. This is easy to track, but slow because each phase waits for the complete closure of the previous one.
In fact, multiple tracks can run in parallel. The selection of packaging can begin as soon as the product category is defined, long before the final formulation. The regulatory preliminary assessment of raw materials can run in parallel with formulation development. The procurement of long lead items can start as soon as the direction is clear.
Start packaging selection in parallel with formulation development.
Conduct regulatory raw material testing in parallel, not downstream.
Procure long-lead items as soon as the category is defined.
Reserve production slots provisionally, and make them binding only after test approval.
The last point deserves careful attention. A slot booked bindingly too early creates pressure to cut testing short. A slot booked too late costs weeks of waiting time. A pre-reservation with a confirmation deadline solves both issues.
Realistic timeline from briefing to delivery
A reliable schedule for an individually developed skincare product typically looks like this. Concept clarification and raw material testing require two to four weeks. The formulation development with samples and adjustment loops takes six to twelve weeks, depending on the number of iterations. After that, the testing phase begins with twelve weeks of stability, alongside microbiology and skin compatibility.
This is followed by the safety assessment and notification taking two to four weeks, then production taking four to eight weeks. In total, this results in six to nine months from briefing to delivery. Anyone planning for three months is not planning ambitiously, but unrealistically, and will experience the difference later as a crisis.
Concept and raw material testing: two to four weeks.
Formulation development including loops: six to twelve weeks.
Testing phase: twelve weeks, partially parallelizable.
Regulatory affairs: two to four weeks.
Production: four to eight weeks.
This span is not a buffer, but the real duration. It can be shortened primarily by reducing the formulation loops, which in turn depends on the quality of the briefing. How to reduce feedback loops is therefore the actual question of acceleration.
A partner who confirms any desired timeline is not a good partner. A plan is only resilient if it specifies which steps are fixed, which can be parallelized, and which decisions must be made by when in order to meet the deadline.
Specifically, you should demand a schedule that outlines the critical path, identifies decision points with dates, and quantifies the consequences of a delayed decision. Without these three elements, a schedule is a declaration of intent, not a plan.
Outlined critical path instead of a simple list of phases.
Decision points with dates and named responsibilities.
Named consequence for each delayed decision, in weeks.
Rules on what happens to costs and deadlines in the event of a failed test.
As a B2B cosmetics developer and manufacturer, Labtree works with precisely this logic: formulation development, in-house laboratory work, and early sampling are managed in such a way that the testing-dependent steps can start as early as possible. This does not shorten the tests, but it shortens the path to getting there.
More useful links
FAQ
How long does the development of a cosmetic product realistically take?
From the briefing to delivery, six to nine months is realistic: two to four weeks for the concept and raw material testing, six to twelve weeks for formulation development with sample loops, twelve weeks for the testing phase, two to four weeks for regulatory compliance, and four to eight weeks for production. Planning with three months is generally unrealistic.
Can the stability testing be shortened?
No. The twelve weeks at elevated temperature are the basis for the shelf-life prediction and cannot be compressed without losing their validity. The only lever is the start date: starting four weeks earlier means launching four weeks earlier. This assumes that the formulation and packaging are finalized correspondingly earlier.
Why does a late packaging decision cause such a major delay?
Because the formulation and packaging material must be tested as a system. Ingredients can migrate, and the packaging can bind preservatives. A change of packaging after the tests are completed invalidates the results, so the twelve weeks start from the beginning. A change in week ten therefore costs twelve weeks, not two.
By when must advertising claims be finalized?
Before the start of test planning. Every efficacy claim must be substantiated according to Regulation 655/2013, and the required proof determines the type and duration of the studies. If claims are only determined after the packaging design is finalized, either the evidence will be missing or the packaging will have to be reprinted.
What can be processed in parallel instead of sequentially?
Packaging selection can start as soon as the product category is determined, which means long before the final formulation. The regulatory raw material review can run in parallel with the formulation development, as can the procurement of long-lead parts. The production slot should be provisionally reserved and only booked bindingly after testing approval.
How do you recognize a robust schedule?
It identifies the critical path, names decision points with dates and responsibilities, and quantifies the consequence of a delayed decision in weeks. A partner who confirms every desired timeline delivers a letter of intent, not a plan.
